Hepatic steatosis evaluated by tomography in an adult population from Cali, Colombia
DOI:
https://doi.org/10.59093/27112330.118Keywords:
fatty liver, non-alcoholic fatty liver disease, multidetector tomography, prevalence.Abstract
Introduction. The primary objective of this study was to determine the prevalence of hepatic steatosis in a Colombian adult population without known medical history, using contrast-enhanced computed tomography density values as a diagnostic test. Additionally, we aimed to compare these results with the known demographic characteristics of the patients and the prevalence reported in the literature. Methodology. A retrospective, descriptive, observational, cross-sectional study was conducted on a population sample of 384 patients who were attended due to abdominal trauma from traffic accidents and abdominal pain as an indication for contrast-enhanced abdominal tomography. A diagnostic cutoff point for steatosis was considered as a difference of -20 HU between hepatic and splenic density in the portal phase. Results. After applying the inclusion and exclusion criteria, 331 patients were selected. Sixty-two patients were identified with hepatic steatosis, of whom 44 were men and 18 were women. A point prevalence of 18.7% for hepatic steatosis was identified in the selected sample. Patients were classified into three age groups: under 30 years with 26/154 positive cases, between 30 and 50 years with 27/118 positive cases, and over 50 years with 9/59 positive cases. Conclusions. The prevalence of hepatic steatosis identified in this study is lower than that reported at the national, South American, and global levels. This result could be related to the selection of a predominantly young adult population without relevant medical history, and the use of more sensitive and specific cutoff points in contrast-enhanced tomography. A high percentage of young patients were identified with hepatic steatosis, implying the need to develop better public health strategies.
Downloads
References
Restrepo-Gutiérrez JC. Una nueva nomenclatura para la enfermedad por hígado graso; producto de muchos y necesarios acuerdos. Hepatol 2022;4:187-188. Disponible en: https://doi.org/10.59093/27112330.97.
Idilman IS, Ozdeniz I, Karcaaltincaba M. Hepatic steatosis: Etiology, patterns, and quantification. Semin Ultrasound CT MR 2016;37:501-510. https://doi.org/10.1053/j.sult.2016.08.003.
Aguilera-Méndez A. Esteatosis hepática no alcohólica: una enfermedad silente. Rev Med Inst Mex Seguro Soc 2018;54:544-549.
Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2022;7:851-861. https://doi.org/10.1016/S2468-1253(22)00165-0.
Prieto-Ortiz JE, Sánchez-Luque CB, Ortega-Quiróz RJ. Hígado graso (parte 1): aspectos generales, epidemiología, fisiopatología e historia natural. Rev Colomb Gastroenterol 2022;37:420-433. https://doi.org/10.22516/25007440.952.
Graffigna M, Catoira N, Soutelo J, Azpelicueta A, Berg G, Perel C, et al. Diagnóstico de esteatosis hepática por métodos clínicos, bioquímicos y por imágenes. Rev Argent Endocrinol Metab 2017;54:37-46. https://doi.org/10.1016/j.raem.2016.12.001.
Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ, et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol 2010;194:623-628. https://doi.org/10.2214/AJR.09.2590.
Wells MM, Li Z, Addeman B, McKenzie CA, Mujoomdar A, Beaton M, et al. Computed tomography measurement of hepatic steatosis: Prevalence of hepatic steatosis in a Canadian population. Can J Gastroenterol Hepatol 2016;2016:4930987. https://doi.org/10.1155/2016/4930987.
Lee DH. Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. Clin Mol Hepatol 2017;23:290-301. https://doi.org/10.3350/cmh.2017.0042.
Kim DY, Park SH, Lee SS, Kim HJ, Kim SY, Kim M-Y, et al. Contrast-enhanced computed tomography for the diagnosis of fatty liver: prospective study with same-day biopsy used as the reference standard. Eur Radiol 2010;20:359-366. https://doi.org/10.1007/s00330-009-1560-x.
Sociedad Española de Radiología Médica (SERAM). XXX Congreso Nacional de la Sociedad Española de Radiología Médica. SERAM: Madrid; 2021. Disponible en: https://seram.es/historico-de-congres/xxx-congreso-nacional-de-la-sociedad-espanola-de-radiologia-medica/.
Hassan R, Abd-Aziz A, Md Ralib AR, Saat A. Computed tomography of blunt spleen injury: a pictorial review. Malays J Med Sci 2011;18:60-67.
Zhang Q-Q, Lu L-G. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol 2015;3:78-84. https://doi.org/10.14218/JCTH.2014.00037.
Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-associated steatotic liver disease (MASLD): A state-of-the-art review. J Obes Metab Syndr 2023;32:197-213. https://doi.org/10.7570/jomes23052.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The authors retain all copyright and grant the Colombian Association of Hepatology a non-exclusive right to publish and disseminate their work.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Hepatología’s authorship policy is based on the criteria established by the International Committee of Medical Journal Editors (ICMJE) to credit a person for their work while assigning them responsibility for its publication.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
